13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

Page 9 of 68

Page 9 of 68 – SEC Filing

13D
CUSIP No. G6503X109
1
NAMES OF REPORTING PERSONS
Philip D. Dreyfuss
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
                                                                                                                                                      (a) [     ]
                                                                                                                                                      (b) [ X ]**
** The reporting persons making this filing hold an aggregate of 3,333,176 ordinary shares (including 675,000 ordinary shares issuable upon the exercise of warrants, which shares may be deemed to be beneficially owned as of the date hereof), which is 26.8% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. [See Item 2(a)]
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
N/A
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e)
                                                                                                                                                            [     ]
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF
SHARES BENEFICIALLY
OWNED BY
EACH
REPORTING  PERSON WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
3,323,6961
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
3,323,6961
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,323,6961
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions)
                                                                                                                                                            [     ]
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.7%
14
TYPE OF REPORTING PERSON (See Instructions)
IN




1 Includes 675,000 ordinary shares issuable upon the exercise of warrants, which shares may be deemed to be beneficially owned as of the date hereof. See Preliminary Note and Item 5.

Follow Nexvet Biopharma Plc (NASDAQ:NVET)

Page 9 of 68